01
Cash & equivalents decreased 15.7%
Cash & equivalents changed -15.7% from the comparable as-filed period.
$12.5M→$10.5MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTROCKWELL MEDICAL, INC.'s latest supported as-filed period reports net income of -$1.2M, 21.4% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -15.7% from the comparable as-filed period.
Gross profit changed +29.6% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Inventory changed -32.3% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
RMTI · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001628280-26-056470SEC ↗10-QAug 13, 2026Period Jun 30, 20260001628280-26-056461SEC ↗8-KAug 13, 2026Period Aug 13, 20260001628280-26-056454SEC ↗8-KJul 20, 2026Period Jul 20, 20260001628280-26-048752SEC ↗4Jul 6, 2026Period Jul 1, 20260001628280-26-047127SEC ↗4Jul 6, 2026Period Jul 1, 20260001628280-26-047126SEC ↗4Jul 6, 2026Period Jul 1, 20260001628280-26-047125SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jul 1, 2026Filed Jul 6, 2026 | Dawson Joseph HDirector | Grant Or AwardDirect | 9,633 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Net income changed +21.4% from the comparable as-filed period.
Operating income changed +21.3% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Research & development changed +0.0% from the comparable as-filed period.
Stock-based compensation changed +5.5% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001628280-26-047121